Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

1.

Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

J Neurol Neurosurg Psychiatry. 2014 Dec 30. pii: jnnp-2014-309243. doi: 10.1136/jnnp-2014-309243. [Epub ahead of print] Review.

PMID:
25550414
3.

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

Cochrane Database Syst Rev. 2014 Jul 26;7:CD009333. doi: 10.1002/14651858.CD009333.pub2. Review.

PMID:
25062935
4.

[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].

Sabanov AV, Luneva AV, Matveev NV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):65-9. Russian.

PMID:
24988963
5.

The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.

Kawalec P, Mikrut A, Wiśniewska N, Pilc A.

Curr Neuropharmacol. 2014 May;12(3):256-68. doi: 10.2174/1570159X12666140115214801.

6.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135
7.

Established and novel disease-modifying treatments in multiple sclerosis.

Cross AH, Naismith RT.

J Intern Med. 2014 Apr;275(4):350-63. doi: 10.1111/joim.12203. Epub 2014 Mar 11. Review.

PMID:
24444048
8.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 6;12:CD009130. doi: 10.1002/14651858.CD009130.pub3. Review.

PMID:
24310855
9.

Management of Relapsing-Remitting Multiple Sclerosis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Oct.

10.

Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.

Brunetti L, Wagner ML, Maroney M, Ryan M.

Ann Pharmacother. 2013 Sep;47(9):1153-60. doi: 10.1177/1060028013500647. Review.

PMID:
24259730
11.

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.

Freedman MS.

Eur J Neurol. 2014 Mar;21(3):377-87, e18-20. doi: 10.1111/ene.12299. Epub 2013 Nov 15. Review.

12.

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.

Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.

Curr Med Res Opin. 2014 Apr;30(4):613-27. doi: 10.1185/03007995.2013.863755. Epub 2013 Nov 26. Review.

PMID:
24195574
13.

Laquinimod for multiple sclerosis.

He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S.

Cochrane Database Syst Rev. 2013 Aug 6;8:CD010475. doi: 10.1002/14651858.CD010475.pub2. Review.

PMID:
23922214
14.

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.

Cochrane Database Syst Rev. 2013 Jun 6;6:CD008933. doi: 10.1002/14651858.CD008933.pub2. Review.

PMID:
23744561
15.

[Teriflunomide for treatment of multiple sclerosis].

Warnke C, Meyer Zu Hörste G, Menge T, Stüve O, Hartung HP, Wiendl H, Kieseier BC.

Nervenarzt. 2013 Jun;84(6):724-31. doi: 10.1007/s00115-013-3779-7. Review. German.

PMID:
23695001
16.

Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.

Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW.

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40. Review.

17.

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Review.

PMID:
23235682
18.

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H.

Neurology. 2012 Sep 11;79(11):1130-5. doi: 10.1212/WNL.0b013e3182698c64. Epub 2012 Aug 29. Review.

19.

Current and emerging therapies in multiple sclerosis: a systematic review.

Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D, Orchard M, Greenberg B, Frohman EM.

Ther Adv Neurol Disord. 2012 Jul;5(4):205-20. doi: 10.1177/1756285612450936.

20.

The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics.

Lindsey J, Scott T, Lynch S, Cofield S, Nelson F, Conwit R, Gustafson T, Cutter G, Wolinsky J, Lublin F; the CombiRx Investigators Group.

Mult Scler Relat Disord. 2012 Apr 1;1(2):81-86. Epub 2012 Feb 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk